Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma.
The clinical utility and acceptable TAT of a comprehensive WES and RNA-seq assay for LBCL managed in routine clinical practice are demonstrated and support the real-world feasibility of using integrated WES and RNA-seq to define molecular subgroups, guide clinical decision-making at the time of a new line of therapy, a...